Roche and Tamiflu come under heavy criticism in new study...

A new study has cast aspersions over the effectiveness of Roche’s antiviral Tamiflu and the company stands accused of not making enough data available to evaluate its risks and benefits properly.

An expert review published by the BMJ says there is no clear evidence that the antiviral most commonly used against influenza – Tamiflu (oseltamivir) - prevents complications like pneumonia in healthy people. The study, which updates a 2006 review published in The Cochrane Library, acknowledges that Tamiflu (and other neuraminidase inhibitors) have a modest effect in reducing flu symptoms and infectivity in otherwise healthy adults by about one day. However, it claims that there is insufficient published data to know if oseltamivir reduces complications in otherwise healthy adults. More...

Don't miss:

1. Novartis opens $1 billion flu vaccine plant in USA...
2. South Korea investigates Roche and Novartis...
3. Novartis and Roche pay millions to US politicians...
4. Kids with flu 'should not take Tamiflu...'
5. Young suffer Tamiflu side-effects...
6. Swine flu alert clears old stock of Tamiflu...
7. British TV host slams Health Secretary over Tamiflu that almost killed his daughter...